An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

(RTTNews) - Daiichi Sankyo (DSKYF.PK) and Merck & Co Inc. (MRK) said that they have reached a global development and commercialization agreement worth up to $22 billion for three of Daiichi Sankyo ...

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2023, it had a debt/adjusted EBITDA ratio of 0.42 times and over JPY 1.2 trillion in ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd.

Daiichi Sankyo and MSD's partnership, which began in October 2023, encompasses the co-development and commercialisation of patritumab deruxtecan (HER3-DXd), raludotatug deruxtecan (R-DXd), and I-DXd.

Daiichi Sankyo agreed to pay Ambit shareholders approximately $315 million upfront through a tender offer followed by a merger with a Daiichi Sankyo subsidiary, plus one Contingent Value Right ...

See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer.

Daiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will manufacture and ...

Daiichi Sankyo agreed to pay $39 million to the U.S. federal government and state Medicaid programs to settle allegations of paying kickbacks to physicians to prescribe several of its drugs.

And then there were four. Late Thursday the FDA announced that it had approved edoxaban, the new oral anticoagulant manufactured by Daiichi Sankyo. The drug will be marketed under the brand name ...